TILYPTIN 20

Indications

• Dehydration
• Electrolyte imbalance
• Heat-related illnesses
• Postoperative recovery
• Diarrhea and vomiting
• Chronic illnesses leading to fluid loss

Dosage

Children: Pediatric dosing should be guided by clinical guidelines and the severity of dehydration. For children experiencing mild to moderate dehydration, ORS is recommended, with the amount based on weight and age. For severe dehydration, intravenous fluid therapy is indicated, with specific protocols available in pediatric guidelines.

Adults: Dosage varies based on the degree of dehydration and the underlying clinical condition. For mild dehydration, oral rehydration solutions (ORS) are often sufficient, while severe cases may require intravenous fluids, with specific rates and types determined by clinical judgment.

Mechanism of action

Hydration works by replenishing lost fluids and electrolytes, restoring osmotic balance and cellular function. The primary components of hydration solutions, such as water, electrolytes (sodium, potassium, chloride), and sometimes glucose, promote proper cellular hydration and support metabolic processes.

Pharmacodynamics

The pharmacodynamics of hydration primarily involves the restoration of plasma volume and the maintenance of electrolyte homeostasis. Proper hydration enhances kidney function, improves cardiovascular stability, and supports normal physiological functions, such as thermoregulation and nutrient transport. It also aids in the recovery of tissues and organs affected by dehydration.

Pharmacokinetics

The pharmacokinetics of hydration solutions depend on the composition of the fluid administered. Oral hydration solutions are absorbed primarily in the gastrointestinal tract, with the rate of absorption influenced by the concentration of electrolytes and glucose. Intravenous fluids can distribute rapidly into the extracellular space, with effects seen almost immediately. The elimination of excess fluids occurs mainly through renal excretion.

Pregnancy

Hydration is essential during pregnancy, but fluid intake should be monitored to avoid excessive hydration, which can lead to complications.

Breast-feeding

Adequate hydration is important during breastfeeding, as it supports milk production. However, excessive fluid intake should be avoided.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Oral solutions
• Intravenous fluids
• Electrolyte solutions

Indications

• Generalized anxiety disorder
• Major depressive disorder
• Panic disorder
• Obsessive-compulsive disorder
• Social anxiety disorder

Dosage

Children: Refer to BNF for Children for appropriate dosing information, as pediatric dosing should be determined based on age, weight, and clinical condition.

Adults: Refer to prescribing guidelines for specific dosing recommendations, as doses may vary based on the condition being treated and individual patient factors.

Mechanism of action

Hydrobomide works by inhibiting the reuptake of serotonin and norepinephrine, two key neurotransmitters in the brain. This inhibition increases the levels of these neurotransmitters in the synaptic cleft, enhancing mood and emotional regulation. Additionally, it may have effects on other neurotransmitter systems, contributing to its overall efficacy in treating anxiety and depressive disorders.

Pharmacodynamics

The pharmacodynamics of hydrobomide involves its interaction with serotonin and norepinephrine transporters. By blocking these transporters, hydrobomide increases the availability of serotonin and norepinephrine. This leads to improved mood, reduced anxiety, and an overall enhancement in emotional well-being. The drug’s effects can vary based on individual patient factors, including genetic variations in drug metabolism.

Pharmacokinetics

Hydrobomide is absorbed following oral administration, with peak plasma concentrations typically occurring within 1 to 3 hours. It is metabolized primarily in the liver, and its metabolites are excreted via the kidneys. The elimination half-life of hydrobomide is variable, depending on the patient's metabolic rate and other factors. Regular monitoring may be required to adjust dosing and manage potential side effects.

Pregnancy

Hydrobomide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare professional for guidance.

Breast-feeding

It is not known if hydrobomide is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• Type 2 diabetes mellitus
• Hyperglycemia in adults with type 2 diabetes

Dosage

Adults: The usual recommended dose of teneligliptin is 20 mg once daily, taken orally. In patients with renal impairment, dose adjustments may be required according to renal function.

Mechanism of action

Teneligliptin inhibits the enzyme DPP-4, which is responsible for the degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, teneligliptin increases the levels of these incretins, leading to enhanced insulin secretion from the pancreatic beta cells and reduced glucagon secretion from the alpha cells. This mechanism helps to lower blood glucose levels in a glucose-dependent manner, thus minimizing the risk of hypoglycemia.

Pharmacodynamics

Teneligliptin exhibits a prolonged duration of action and has a favorable pharmacodynamic profile, leading to improved glycemic control in patients with type 2 diabetes. The increase in incretin hormones contributes to improved beta-cell function and insulin sensitivity. Additionally, teneligliptin may also have beneficial effects on body weight and lipid metabolism, making it a suitable option for overweight patients with type 2 diabetes.

Pharmacokinetics

Teneligliptin is absorbed rapidly following oral administration, with peak plasma concentrations typically reached within a few hours. It has a bioavailability of approximately 60-70%. The drug is extensively metabolized in the liver, primarily via the CYP3A4 pathway, with its elimination occurring mainly through renal excretion. The half-life of teneligliptin is around 10-12 hours, which allows for once-daily dosing. Factors such as renal impairment may necessitate dosage adjustments.

Contra-indications

• Hypersensitivity to teneligliptin or any of its components
• Severe renal impairment (eGFR < 15 mL/min)
• Diabetic ketoacidosis

Adverse effects

• Hypoglycemia
• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Headache
• Dizziness
• Pancreatitis
• Allergic reactions (rash, pruritus)

Interactions

• Caution with concomitant use of medications that affect glycemic control
• May interact with other antidiabetic agents, which can increase the risk of hypoglycemia
• Potential interaction with strong CYP3A4 inhibitors and inducers

Precautions

• Monitor renal function regularly
• Use with caution in patients with a history of pancreatitis
• Adjust dose in elderly patients or those with renal impairment

Pregnancy

There is limited data on the use of teneligliptin in pregnancy. It should only be used if the benefits outweigh the risks.

Breast-feeding

It is not known if teneligliptin is excreted in human milk. Caution should be exercised when administered to breastfeeding women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets of 20 mg